An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy
Inclusion Criteria:
Exclusion Criteria:
Capital Federal, Buenos Aires 1426, Argentina
Ciudad Autonoma de Buenos Aire, Buenos Aires 1181, Argentina
Ostrava - Poruba, 708 52, Czechia
Habikino-shi, Osaka 5638588, Japan
Miyakojima-ku, Osaka 534-0021, Japan
Kitaadachi-gun, Saitama 3620806, Japan
Sunto-gun, Shizuoka 4118777, Japan
Chuo-ku, Tokyo 1040045, Japan
Akashi, Hyogo, 673-8558, Japan
Gangnam-gu, 06351, South Korea